|Bid||0.00 x 6700|
|Ask||0.00 x 11200|
|Day's range||81.80 - 82.78|
|52-week range||80.92 - 115.20|
|PE ratio (TTM)||19.29|
|Earnings date||15 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Reckitt Benckiser (Xetra: A0M1W6 - news) 's shares sank after the British consumer goods group missed 2017 profit estimates, while tough trading conditions and rising commodity costs hit its outlook. Another factor weighing on Reckitt's shares was the heightened expectation of it buying the consumer health business being sold by Pfizer (NYSE: PFE - news) , which could potentially dilute shareholders through an equity capital increase. Reckitt's shares were down more than 7 percent at 1614 GMT in the biggest fall by a European blue-chip stock.
Merck KGaA and Pfizer (NYSE: PFE - news) received a setback on Thursday for their drug Bavencio, which is a late starter in the rapidly evolving field of cancer immunotherapies. In the late stage trial of Bavencio, the drug could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said.
FRANKFURT (Reuters) - Merck KGaA and Pfizer's cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said. The ...
LONDON/FRANKFURT (Reuters) - The sale of Merck KGaA's consumer health unit has been thrown off track after Nestle has pulled out, leaving the race to buy the maker of Seven Seas vitamins without its main contender, sources familiar with the matter told Reuters. Nestle has walked away from the process, led by JPMorgan, after months of negotiations as the Swiss company was put off by Merck's price expectations of about 4 billion euros ($4.99 billion), the sources said. Nestle and Merck declined to comment.
LONDON/FRANKFURT (Reuters) - The sale of Merck KGaA's (MRCG.DE) consumer health unit has been thrown off track after Nestle (NESN.S) has pulled out, leaving the race to buy the maker of Seven Seas vitamins without its main contender, sources familiar with the matter told Reuters. Nestle has walked away from the process, led by JPMorgan (JPM.N), after months of negotiations as the Swiss company was put off by Merck's price expectations of about 4 billion euros ($4.99 billion), the sources said. Nestle and Merck declined to comment.
Merck, a leading science and technology company, leverages its Consumer Health business' strong momentum, by launching several new programmes for the WE100 umbrella movement of the business and for two of its iconic brands. The We100 movement was established to bring the Consumer Health business purpose to life which aims to help prepare society for a new era of humans living 100 healthy years. After publishing a whitepaper (http://www.merckgroup.com/en/expertise/consumer-health/our-consumer-health-debate/white-paper.html ) in November 2017 shedding light on how to prepare younger generations to live 100 healthy years, the Consumer Health business of Merck continues to pursue its ambitious goal to help bridging the gap between "living longer" and "living longer and healthier".
LONDON/MILAN, Jan 16 (Reuters) - Swiss food group Nestle has agreed to sell its U.S. confectionery business to Italy's Ferrero for $2.8 billion, it said on Tuesday, marking CEO Mark Schneider's first big sale and a small step on its path towards healthier products. Nestle, the world's biggest packaged-food company, has cited the unit's weak position in the United States, where it trails Hershey, Mars Inc and Lindt, as the rationale for a sale. For family-owned Ferrero, the cash deal offers a chance for the Italian company to build scale quickly in that key market, where it has done two other deals in the past year.
ZURICH (Reuters) - Nestle (NESN.S) is the frontrunner to buy Merck KGaA's (MRCG.DE) consumer health unit that could fetch as much as $5 billion, financial news service Bloomberg said on Wednesday, quoting ...
Nestle is the frontrunner to buy Merck KGaA's consumer health unit that could fetch as much as $5 billion, financial news service Bloomberg said on Wednesday, quoting unidentified sources familiar with ...
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications today announced a new Master Collaboration Agreement for translational programs with Merck KGaA, Darmstadt, Germany, a leading science and technology company. The Master Collaboration Agreement complements the previously announced Master Companion Diagnostic Agreement with Merck KGaA, Darmstadt, Germany and includes a statement of work with EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the United States and Canada.
Germany's Merck KGaA (MRCG.DE) is reviving plans to bring an oral multiple sclerosis (MS) treatment to the U.S. market, hoping for blockbuster sales despite regulatory concerns about side effects having frustrated its ambitions almost seven years ago. In early 2011 the U.S. regulator's concerns put an end to Merck's development plans for the cladribine pill, now branded as Mavenclad, but Merck later revived efforts by focusing on the most severely affected patients and won approval in Europe in August this year. Merck, whose products include high-tech chemicals, laboratory equipment and cancer drugs, has now decided also to file for approval with the U.S. Food and Drug Administration (FDA) in the second quarter of 2018, the head of its healthcare division, Belen Garijo, told Reuters.
LONDON/FRANKFURT (Reuters) - Generic drugmaker Perrigo (PRGO.N) has decided to enter the fray for Merck KGaA's (MRCG.DE) consumer health unit, sources told Reuters, and is preparing an indicative offer for the $4.7 billion business ahead of a deadline on Friday. Perrigo is expected to face competition from Swiss food giant Nestle (NESN.S) and the private equity owners of German drug firm Stada (STAGn.DE), which are also lining up non-binding offers for the maker of Seven Seas vitamins and Bion nutritional supplements, the sources said on Thursday. Merck's financial adviser JPMorgan wants to shortlist bidders for the business before the end of the year, they said.
Merck, a leading science and technology company, today announced the FDA 510(K) clearance of the benchtop embryo incubator Geri™. This innovative technology, designed to improve processes in fertility laboratories, will be commercially available to IVF clinics in the U.S. in the first half of 2018.
Buyout group Nordic Capital has agreed to buy Alloheim, one of Germany's top three nursing home operators, for about 1.1 billion euros including debt, sources close to the matter said. Alloheim owner Carlyle ...
LONDON/FRANKFURT (Reuters) - Swiss food giant Nestle (NESN.S) and the private equity owners of German drug firm Stada (STAGn.DE) are both preparing tentative bids for Merck KgaA's (MRCG.DE) consumer health unit, several sources told Reuters. Merck's financial adviser JPMorgan has invited bids for the business, which is valued at about 4 billion euros (£3.5 billion), ahead of a Dec. 15 deadline, the sources said. Nestle is widely seen as a natural buyer for the maker of Seven Seas vitamins and Bion nutritional supplements, after previous talks to set up a consumer joint venture with Merck fell through over the summer.
Germany's Merck KGaA has suffered a setback in the development of key cancer immunotherapy Bavencio, it having failed in a trial to prolong lives in gastric cancer patients when compared with standard ...
Pfizer Inc. and German-based Merck KGaA said Tuesday a phase 3 trial of a cancer treatment did not meet its primary endpoint of superior overall survival. Pfizer's stock slipped 0.9% in premarket trade. ...
Merck, a leading science and technology company, today announced that the company received approval for a new version of GONAL-f® (follitropin alfa injection) prefilled pen from the U.S. Food and Drug Administration (FDA). "Aspiring to be an integrated fertility treatment partner, our strategy focuses on developing user-friendly treatment options for patients," said Luciano Rossetti, Head of Global Research and Development, at the biopharma business of Merck. To date, an estimated 2.5 million babies have been brought to the world with the help of Merck fertility products and services. GONAL-f® is the only gonadotropin that comes in prefilled, ready-to-use pen in the U.S. The new GONAL-f® pen, like its predecessor, enables a fine-tuning of treatment allowing for minimum increments of 12.5 IU to titrate a wide range of doses and precisely target the dosing to patients' needs. In addition, its new design features include an amendment to the dose display window for readability.
Merck, a leading science and technology company with 60 years of clinical experience in diabetes, today announced its partnership with the International Diabetes Federation (IDF) to implement education and communications activities emphasizing the importance of preventing type 2 diabetes.
Merck KGaA (MKGAF) reported dismal third-quarter results with earnings declining year over year. Revenues were flat amid continued negative currency movement.
Merck, a leading science and technology company, today announced that the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom (UK) has issued a final appraisal determination (FAD) recommending Cladribine Tablets (MAVENCLAD®) as an option for treating highly active multiple sclerosis* in adults.1 Use of Cladribine Tablets is recommended only if the person has: rapidly evolving severe relapsing-remitting multiple sclerosis, that is, at least two relapses in the previous year and at least one T1 gadolinium-enhancing1 lesion at baseline MRI or relapsing-remitting multiple sclerosis that has responded inadequately to treatment with disease-modifying therapy, defined as one relapse in the previous year and MRI evidence of disease activity.
By Ludwig Burger FRANKFURT (Reuters) - Germany's Merck KGaA (MRCG.DE) said it was targeting the lower end of its forecast ranges for 2017 results after a stronger euro inflated costs, though double-digit ...
Nov.09 -- Merck Kgaa CFO Marcus Kuhnert discusses the company's earnings and performance. He speaks on "Bloomberg Markets."